Karine Rossignol, Smart Immune CEO (Laurent Attias/Smart Immune)
November 15, 2023 07:39 AM ESTUpdated 10:27 AM
Financing
Cell/Gene Tx

Scoop: Smart Im­mune tar­gets $54M Se­ries A to ad­vance T cell prog­en­i­tor ther­a­py: #Jef­feries23

Ayisha Sharma

News Reporter

French biotech Smart Im­mune has raised more than half of its rough­ly €50 mil­lion ($54 mil­lion) tar­get in an on­go­ing Se­ries A round, with an …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Bridge­Bio shares promis­ing re­sults in tri­al of Cana­van dis­ease gene ther­a­py

CRISPR ther­a­py re­duces swelling at­tacks by 81% in In­tel­lia fol­low-up study

Fac­ing lost re­bates, MGM Re­sorts to stop cov­er­ing GLP-1 weight loss shots

Ex­clu­sive: Uni­ver­si­ty of Toron­to spin­out rais­es $53.5M to cre­ate new obe­si­ty drugs with AI

Icon's quar­ter­ly earn­ings hit by biotech and phar­ma pull­back

sponsored

IDEAYA Bio­sciences: Tar­get­ing un­met mar­ket needs with pre­ci­sion on­col­o­gy

A service from the Financial Times